RxDoctor Payments Data

Barbara Wojda, MD

Infectious Disease · Louisville, KYNPI 1225049661

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 75.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $4,959 and has fallen 97.6% since, to $119 in 2025.

$7,028in general payments, 2019–2025

Across 126 payments — averaging $55.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$5K
  • Astellas Pharma US Inc$390
  • Insmed, Inc.$269
  • Merck$243
  • AbbVie$217
  • Pfizer$200
  • plus $378 from 9 others

What the payments were for

  • Consulting fees$3,14045%
  • Travel & lodging$1,46621%
  • Food & beverage$2,35233%
  • Education$711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,028 in reported general payments places this provider in the 80th percentile of 100 infectious disease providers in Kentucky.

See all infectious disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$6,086
Medicare patients
23
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala289$1,100,838
TriumeqAbacavir/Dolutegravir/Lamivudi92$311,595
RukobiaFostemsavir Tromethamine13$115,252
DovatoDolutegravir Sodium/Lamivudine40$114,114
CabenuvaCabotegravir/Rilpivirine18$109,663
OdefseyEmtricitab/Rilpiviri/Tenof Ala31$109,530
GenvoyaElviteg/Cob/Emtri/Tenof Alafen25$97,698
TivicayDolutegravir Sodium43$94,924
DescovyEmtricitabine/Tenofov Alafenam17$36,487
PrezcobixDarunavir/Cobicistat12$28,598
IsentressRaltegravir Potassium14$27,388
PifeltroDoravirine14$23,465
Etravirine19$20,882
ReyatazAtazanavir Sulfate11$15,130
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)14$3,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$5,331$1,235,023331 claims
Viiv Healthcare CompanyTriumeq, Rukobia, Dovato, Cabenuva, Tivicay$28$745,549206 claims
MerckIsentress, Pifeltro$243$50,85228 claims
Johnson & JohnsonPrezcobix$42$28,59812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 100 infectious disease providers in Kentucky.

Other infectious disease in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →